Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy

Inclusion Criteria: * male patients suffering from LUTS lasting 6months and over * male patients aged 50 years old and over who has a continuous active partner Exclusion Criteria: * Primary hypogonadism and neuropathy patients * History of prostate surgery * Patients with prostate cancer * History of organ surgery or organ damage in pelvis * History of myocardiac infarction, stroke, and life threatening arrythmia within last 6 months * Patients with haematuria caused by other reasons except BPH * Patients with uncontrolled hypertension in spite of treatment with antihypertensive agents * History of a malignant tumor within last 5 years * Patients who are currently controlled with other medication for erectile dysfunction * Patients who have been administered with androgen or antiandrogen * Patients who is treated for psychiatric disorder or depression * Combination with other alpha1-blockers * Patients previously not improved by an alpha1-blocker treatment * Known hypersensitivity to the alfuzosin * History of postural hypotension or syncope * Hepatic insufficiency * Unstable angina pectoris The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.